Immunome, Inc.IMNMNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -28.44% | +184.35% | +69.84% | -100.00% | -100.00% |
| Gross Profit Growth | -28.44% | +184.35% | +39.38% | -1790.48% | -128.34% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +185.66% | +670.31% | +45.17% | +46.10% | +39.31% |
| Weighted Average Shares Diluted Growth | +185.66% | +670.31% | +45.17% | +46.10% | +39.31% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +61.73% | +7.17% | +0.03% | +16.54% | +184.38% |
| Book Value per Share Growth | -47.10% | -86.04% | -26.93% | -15.94% | +151.35% |
| Debt Growth | +192.85% | +193.54% | +49.42% | +47.48% | -20.22% |
| R&D Expense Growth | +396.94% | +139.91% | +39.09% | +32.24% | +6.01% |
| SG&A Expenses Growth | +29.93% | +78.02% | +43.91% | +14.90% | +8.32% |